Promising new advances in head and neck radiotherapy

Annals of Oncology

Volumn 16, Issue SUPPL. 6, 2005, Pages

  Harari, P M ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Cetuximab; EGFR; Head and neck cancer; Radiation; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; MITOMYCIN; MONOCLONAL ANTIBODY R3; PANITUMUMAB; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DRUG FATALITY; DRUG MECHANISM; DYSPHAGIA; FIBROSIS; HEAD AND NECK CANCER; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RADIATION EXPOSURE; RISK REDUCTION; SKIN TOXICITY; STOMATITIS; XEROSTOMIA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DOSE FRACTIONATION; HEAD AND NECK NEOPLASMS; HUMANS; RADIOTHERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 27144509126     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi453     Document Type: Article

References (55)

1. Trotti A, Bellm LA, Epstein JB et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: A systematic literature review. Radiother Oncol 2003; 66: 253-262.
2. Chambers MS, Garden AS, Kies MS, Martin JW. Radiation-induced xerostomia in patients with head and neck cancer: Pathogenesis, impact on quality of life, and management. Head Neck 2004; 26: 796-807.
3. Nguyen LN, Ang KK. Radiotherapy for cancer of the head and neck: Altered fractionation regimens. Lancet Oncol 2002; 3: 693-701.
4. Bourhis J, Etessami A, Wilbault P et al. Altered fractionated radiotherapy in the management of head and neck carcinomas: Advantages and limitations. Curr Opin Oncol 2004; 16: 215-219.
5. Overgaard J, Hansen HS, Specht L et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomized controlled trial. Lancet 2003; 362: 933-940.
6. Fu KK, Pajak TF, Trotti A et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000; 48: 7-16.
7. Khalil AA, Bentzen SM, Bernier J et al. Compliance to the prescribed dose and overall treatment time in five randomized clinical trials of altered fractionation in radiotherapy for head-and-neck carcinomas. Int J Radiat Oncol Biol Phys 2003; 55: 568-575.
8. Awwad HK, Lotayef M, Shouman T et al. Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the post-operative radiotherapy of locally advanced head and neck cancer: Influence of proliferation. Br J Cancer 2002; 86: 517-523.
9. Zackrisson B, Mercke C, Strander H et al. A systematic overview of radiation therapy effects in head and neck cancer. Acta Oncol 2003; 42: 443-461.
10. Bourhis J, De Crevoisier R, Abdulkarim B et al. A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2000; 46: 1105-1108.
11. Teh BS, Woo SY, Butler EB. Intensity modulated radiation therapy (IMRT): a new promising technology in radiation oncology. Oncologist 1999; 4: 433-442.
12. Ozyigit G, Yang T, Chao KS. Intensity-modulated radiation therapy for head and neck cancer. Curr Treat Options Oncol 2004; 5: 3-9.
13. Chao KS, Ozyigit G, Blanco AI et al. Intensity-modulated radiation therapy for oropharyngeal carcinoma: Impact of tumor volume. Int J Radiat Oncol Biol Phys 2004; 59: 43-50.
14. Eisbruch A, Marsh LH, Dawson LA et al. Recurrences near base of skull after IMRT for head-and-neck cancer: Implications for target delineation in high neck and for parotid gland sparing. Int J Radiat Oncol Biol Phys 2004; 59: 28-42.
15. Huang K, Lee N, Xia P et al. Intensity-modulated radiotherapy in the treatment of oropharyngeal carcinoma: A single institutional experience. Int J Radiat Oncol Biol Phys 2003; 57 (Suppl): S302.
16. Garden AS, Morrison WH, Wong P et al. Preliminary results of intensity modulated radiation therapy for small primary oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2003; 57 (Suppl): S407.
17. Hong TS, Tome WA, Chappell RJ et al. The impact of daily setup variations on head-and-neck intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2005; 61: 779-788.
18. Gregoire V, Maingon P. Intensity-modulated radiation therapy in head and neck squamous cell carcinoma: An adaptation of 2-dimensional concepts or a reconsideration of current clinical practice. Semin Radiat Oncol 2004; 14: 110-120.
19. Hong TS, Tomé WA, Chappell RJ, Harari PM. Variations in target delineation for head and neck IMRT: An international multi-institutional study. Int J Radiat Oncol Biol Phys 2004; 60 (Suppl 1): S157-S158 (abstr).
20. Mell LK, Roeske JC, Mundt AJ. A survey of intensity-modulated radiation therapy use in the United States. Cancer 2003; 98: 204-211.
21. Chao KS, Ozyigit G, Thorsdad WL. Toxicity profile of intensity-modulated radiation therapy for head and neck carcinoma and potential role of amifostine. Semin Oncol 2003; 30: 101-108.
22. Ling CL, Chui C, Losasso T et al. Intensity-modulated radiation therapy. Cancer: Principles and practice of oncology. 2001. Lippincott, Williams & Wilkins. Philadelphia. pp. 777-788.
23. Beavis AW. Is tomotherapy the future of IMRT? Br J Radiol 2004; 77: 285-295.
24. Welsh JS, Patel RR, Ritter MA et al. Helical tomotherapy: An innovative technology and approach to radiation therapy. Technol Cancer Res Treat 2002; 1: 311-316.
25. Bernier J, Domenge C, Ozsahin M et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350: 1945-1952.
26. Cooper JS, Pajak TF, Forastiere AA et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350: 1937-1944.
27. Bieri S, Bentzen SM, Huguenin P et al. Early morbidity after radiotherapy with or without chemotherapy in advanced head and neck cancer. Experience from four nonrandomized studies. Strahlenther Onkol 2003; 179: 390-395.
28. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000; 355: 949-955.
29. Browman GP, Hodson DI, Mackenzie RJ et al. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: A systematic review of the published literature with subgroup analysis. Head Neck 2001; 23: 579-589.
30. El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. J Clin Oncol 1996; 14: 838-847.
31. Munro AJ. An overview of randomized controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 1995; 71: 83-91.
32. Stell PM, Rawson NS. Adjuvant chemotherapy in head and neck cancer. Br J Cancer 1990; 61: 779-787.
33. Goldstein NI, Prewett M, Zuklys K et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995; 1: 1311-1318.
34. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: Implications for a standardized scoring system. Cancer 2001; 92: 1331-1346.
35. Grandis JR, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996; 78: 1284-1292.
36. Ang KK, Berkey BA, Tu X et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62: 7350-7356.
37. Hitt R, Castellano D, Ciruelos E et al. Overexpression of epidermal growth factor receptor (EGFR) and p53 mutations levels as prognostic factors in patients with locally-advanced head and neck cancer (LAHNC) treated with induction chemotherapy. Proc Am Soc Clin Oncol 2002; 22: Abstr 972.
38. Maurizi M, Almadori G, Ferrandina G et al. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer 1996; 74: 1253-1257.
39. Harari PM, Huang SM. Head and neck cancer as a clinical model for molecular targeting of therapy: Combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 2001; 49: 427-433.
40. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59: 1935-1940.
41. Milas L, Mason K, Hunter N et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000; 6: 701-708.
42. Harari PM, Huang SM. Combining EGFR inhibitors with radiation or chemotherapy: Will preclinical studies predict clinical results? Int J Radiat Oncol Biol Phys 2004; 58: 976-983.
43. Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 2004; 11: 689-708.
44. Robert F, Ezekiel MP, Spencer SA et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001; 19: 3234-3243.
45. Bonner JA, Giralt J, Harari P et al. Cetuximab prolongs survival in patients with locally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22 (No 14S): Abstr 5507.
46. Harari PM, Chinnaiyan P, Durland W et al. Surgical wound healing in advanced head and neck cancer patients undergoing neck dissection following high dose radiation +/- cetuximab. Int J Radiat Oncol Biol Phys 2003; 57: S245-S246.
47. Pfister DG, Aliff TB, Kraus DH et al. Concurrent cetuximab, cisplatin, and concomitant boost radiation therapy (RT) for locoregionally advanced, squamous cell head and neck cancer (SCCHN): Preliminary evaluation of a new combined-modality paradigm. Proc Am Soc Clin Oncol 2003; 22: Abstr 1993.
48. Cohen EE, Rosen F, Stadler WM et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21: 1980-1987.
49. Kane MA, Cohen EE, List M et al. Phase II study of 250 mg gefitinib in advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22 (No 14S): Abstr 5586.
50. Soulieres D, Senzer NN, Vokes EE et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22: 77-85.
51. Rhoades CA, Kraut E, Schuller DE et al. Phase I and II study of OSI-774 and docetaxel in squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22 (No 14S): Abstr 5541.
52. Crombet T, Osorio M, Cruz T et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004; 22: 1646-1654.
53. Meropol NJ, Berlin J, Hecht JR et al. Multicenter study of ABX-EGF monotherapy in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2003; 22: Abstr 1026.
54. Huang S, Armstrong EA, Benavente S et al. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): Combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 2004; 64: 5355-5362.
55. Matar P, Rojo F, Cassia R et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): Superiority over single-agent receptor targeting. Clin Cancer Res 2004; 10: 6487-6501.